Table 3 EORTC-QLQ30 items results at diagnosis and during follow-up evaluation
From: Palliative treatment of endometrial cancer: what is the role of anastrozole in elderly women?
EORTC-QLQc30 | Mean (±SD) | P | |||
|---|---|---|---|---|---|
Baseline (0) | Six months (6) | Twelve months (12) | 0 vs 6 | 0 vs 12 | |
GH | 64.58 (10.68) | 69.79 (6.2) | 76.04 (8.26) | 0.156 | 0.002 |
PF | 86.67 (11.27) | 88.33 (9.92) | 86.67 (10.69) | 0.470 | 1 |
RF | 97.92 (5.89) | 100 (0) | 93.75 (8.63) | 0.401 | 0.093 |
EF | 93.75 (7.39) | 92.71 (5.34) | 96.88 (6.2) | 0.628 | 0.146 |
CF | 100 (0) | 95.83 (7.72) | 97.92 (5.89) | 0.131 | 0.450 |
SF | 100 (0) | 100 (0) | 100 (0) | 1 | |
FA | 6.94 (8.27) | 16.67 (14.55) | 11.11 (11.88) | 0.011 | 0.276 |
NV | 0 (0) | 0 (0) | 0 (0) | ||
PA | 8.33 (8.91) | 6.25 (8.63) | 2.08 (5.89) | 0.488 | 0.038 |
DY | 12.5 (17.25) | 16.67 (17.82) | 12.5 (17.25) | 0.190 | 1 |
SL | 37.5 (27.82) | 20.83 (24.8) | 16.67 (17.82) | 0.008 | 0.001 |
AP | 0 (0) | 0 (0) | 0 (0) | ||
CO | 8.33 (15.43) | 0 (0) | 8.33 (15.43) | 0.121 | 1 |
DI | 0 (0) | 0 (0) | 0 (0) | ||
FI | 0 (0) | 0 (0) | 0 (0) | ||